[
    {
      "id": 1,
      "title":"Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)",
      "created_by": "Dr.Jane Anderson",
      "description": "The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for CVD to be randomized 1:1 to either corn oil + statin or Epanova + statin, once daily, for approximately 3-5 years as determined when the number of MACE outcomes is reached.",
      "Condition": "Breast Neoplasms",
      "Sponsor": "AstraZeneca",
      "Identified": "88,654",
      "Pre_Screened": "50,846",
      "Qualified":"2,351",
      "Enrolled":"568"
    },
      {
      "id": 2,
      "title":"Can Hypothermia be Incorporated Into Primary Angioplasty for Heart Attack?",
      "created_by": "Dr.Robert J Freedman",
      "description": "The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.",
      "Condition": "Breast Cancer",
      "Sponsor": "AstraZeneca",
      "Identified": "16,451",
      "Pre_Screened": "5,143",
      "Qualified":"1,310",
      "Enrolled":"650"
    },
      {
      "id": 3,
      "title":"Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStentÂ® System)",
      "created_by": "Dr.Yaling Han",
      "description": "The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.",
      "Condition": "Coronary Heart Disease",
      "Sponsor": "Micell Technologies",
      "Identified": "66,258",
      "Pre_Screened":"30,146",
      "Qualified":"8,554",
      "Enrolled":"2,026"
    },
      {
      "id": 4,
      "title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer",
      "created_by": "Dr.Jane Anderson",
      "description": "The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.",
      "Condition": "Non-small Cell Lung Carcinoma",
      "Sponsor": "AstraZeneca",
      "Identified": "2,654",
      "Pre_Screened": "946",
      "Qualified":"751",
      "Enrolled":"569"
    },
     {
      "id": 5,
      "title":"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis",
      "created_by": "Dr.Jane Anderson",
      "description": "The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.",
      "Condition": "Lupus Nephritis",
      "Sponsor": "Human Genome Sciences Inc",
      "Identified": "21,745",
      "Pre_Screened": "15,482",
      "Qualified":"4,351",
      "Enrolled":"1,695"
    },
    {
      "id": 6,
      "title":"A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer",
      "created_by": "Dr.Jane Anderson",
      "description": "The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.",
      "Condition": "NSCLC",
      "Sponsor": "Hutchison Medipharma Limited",
      "Identified": "15,151",
      "Pre_Screened": "8,846",
      "Qualified":"3,335",
      "Enrolled":"2,360"
    },
    {
      "id": 7,
      "title":"EINSTEIN Junior Phase III: Oral Rivaroxaban in Children With Venous Thrombosis",
      "created_by": "Dr.Jane Anderson",
      "description": "The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.",
      "Condition": "Venous Thromboembolism",
      "Sponsor": "Bayer",
      "Identified": "2,654",
      "Pre_Screened": "946",
      "Qualified":"751",
      "Enrolled":"269"
    },
     {
      "id": 8,
      "title":"Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma",
      "created_by": "Dr.Jane Anderson",
      "description": "The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.",
      "Condition": "Hepatocellular Carcinoma",
      "Sponsor": "Taiwan Liposome Company",
      "Identified": "88,654",
      "Pre_Screened": "50,846",
      "Qualified":"2,351",
      "Enrolled":"365"
    }
]
